Form 483

Private Label Partners, Inc. Form 483, 2025-01-17

FDA issued a Form 483 to Private Label Partners, Inc. on 2025-01-17 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Private Label Partners, Inc. · Santa Ana, United States · Issued January 17, 2025

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

17 Jan 2025
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Andrew Le, Lena Nguyen

17 Jan 2025
21 CFR 211.165(a)

Testing and release for distribution

Cited by Andrew Le, Lena Nguyen

17 Jan 2025
21 CFR 211.166(a)

Written program not followed

Cited by Andrew Le, Lena Nguyen

17 Jan 2025
21 CFR 211.188

Prepared for each batch, include complete information

Cited by Andrew Le, Lena Nguyen

17 Jan 2025
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Andrew Le, Lena Nguyen

Inspected site

PLPrivate Label Partners, Inc.Santa Ana, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.188Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere